Analyst Ratings for Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has received mostly bullish ratings from analysts, with 19 bullish, 4 somewhat bullish, and 7 indifferent. In the last 3 months, 30 analysts have offered 12-month price targets for Apellis Pharmaceuticals, with an average price target of $68.03, a decrease of 17.2% from the previous average price target of $82.16.
October 06, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals has received mostly bullish ratings from analysts, indicating a positive outlook for the stock. However, the average price target has decreased by 17.2%.
The majority of analysts are bullish on Apellis Pharmaceuticals, which is generally a positive sign for the stock. However, the decrease in the average price target could indicate that analysts are less optimistic about the company's future performance than they were previously.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100